[{"orgOrder":0,"company":"Formycon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FYB206","moa":"IL-12","graph1":"Oncology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Formycon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Undisclosed"},{"orgOrder":0,"company":"Formycon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FYB206","moa":"IL-12","graph1":"Oncology","graph2":"Phase I","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Formycon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Formycon \/ Undisclosed"},{"orgOrder":0,"company":"Formycon","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Formycon \/ Formycon"},{"orgOrder":0,"company":"Formycon","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Bioeq IP AG","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Bioeq IP AG"},{"orgOrder":0,"company":"Formycon","sponsor":"Fresenius SE & Co. KGaA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formycon \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Formycon \/ Formycon"},{"orgOrder":0,"company":"Formycon","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0.71999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.71999999999999997,"dosageForm":"Injection","sponsorNew":"Formycon \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Formycon"},{"orgOrder":0,"company":"Formycon","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0.71999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.71999999999999997,"dosageForm":"Injection","sponsorNew":"Formycon \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Formycon"},{"orgOrder":0,"company":"Formycon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"FYB201","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Formycon \/ Undisclosed"},{"orgOrder":0,"company":"Formycon","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Formycon \/ Formycon"},{"orgOrder":0,"company":"Formycon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Undisclosed"},{"orgOrder":0,"company":"Formycon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Undisclosed"},{"orgOrder":0,"company":"Formycon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"FYB203","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Formycon \/ Undisclosed"},{"orgOrder":0,"company":"Formycon","sponsor":"Horus Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Protein","year":"2025","type":"Partnership","leadProduct":"Aflibercept","moa":"VEGF-A | PlGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Horus Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Formycon \/ Horus Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Formycon

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The partnership aims for the commercialization of Formycon's Eylea biosimilar FYB203, under the brand name Baiama, in selected European countries.

                          Product Name : Baiama

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          September 17, 2025

                          Lead Product(s) : Aflibercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Horus Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : FYB201 is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Macular Degeneration.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          November 27, 2024

                          Lead Product(s) : FYB201

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : FYB203 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Macular Degeneration.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          November 27, 2024

                          Lead Product(s) : FYB203

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : FYB206 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 16, 2024

                          Lead Product(s) : FYB206

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Otulfi (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                          Product Name : Otulfi

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          September 30, 2024

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Recipient : Fresenius SE & Co. KGaA

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : FYB206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 13, 2024

                          Lead Product(s) : FYB206

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : FYB202 (ustekinumab biosimilar) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin 23 for treatment of immune-mediated disorders.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 07, 2023

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Recipient : Fresenius Kabi AG

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The structure of the transaction will involve Formycon acquiring all the rights in FYB202, a biosimilar candidate for Stelara® (ustekinumab), as well as a 50% share in FYB201, a biosimilar candidate for Lucentis®2 (ranibizumab).

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          May 10, 2022

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Recipient : ATHOS

                          Deal Size : $720.7 million

                          Deal Type : Acquisition

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The structure of the transaction will involve Formycon acquiring all the rights in FYB202, a biosimilar candidate for Stelara® (ustekinumab), as well as a 50% share in FYB201, a biosimilar candidate for Lucentis®2 (ranibizumab).

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          March 29, 2022

                          Lead Product(s) : Ustekinumab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Recipient : ATHOS

                          Deal Size : $720.7 million

                          Deal Type : Acquisition

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : FYB201 (Ranibizumab) is used in treatment of various eye diseases in adults which cause damage to retina, thereby impairing vision. In these diseases, protein called VEGF causes excessive blood vessels to form within retina, resulting in a progressive lo...

                          Product Name : Cimerli

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 06, 2021

                          Lead Product(s) : Ranibizumab

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Recipient : Bioeq IP AG

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank